

Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Body Mass Index (BMI) fluctuations play a crucial role in shaping clinical outcomes among leukemia patients concurrently diagnosed with HIV/AIDS. In this review, we delve into the multifaceted relationship between BMI variations and disease trajectories in this vulnerable population. BMI serves as a vital indicator of nutritional status and immune competence, with deviations from the norm posing significant challenges to therapeutic efficacy and patient well-being. The papers explore the impact of BMI on treatment responses, immunological function, and overall survival, shedding light on the complex interplay between metabolic health and disease progression. Additionally, the paper discusses emerging strategies for personalized interventions aimed at optimizing clinical outcomes and enhancing quality of life in leukemia patients with HIV/AIDS, emphasizing the importance of a multidisciplinary approach encompassing nutritional support, pharmacological interventions, and psychosocial care.

Keywords: *Body Mass Index, Leukemia, HIV/AIDS, Clinical Outcomes, Nutrition, Immune Function, Treatment Response*

Introduction

Leukemia, a hematological malignancy characterized by aberrant proliferation of blood cells, and HIV/AIDS, a viral infection that compromises immune function, represent formidable challenges

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

to global public health.¹⁻² Concurrent diagnosis of these conditions presents a complex clinical scenario fraught with unique considerations. Body Mass Index (BMI), a measure derived from an individual's weight and height, emerges as a critical parameter in assessing nutritional status and overall health, particularly in patients grappling with the dual burden of leukemia and HIV/AIDS.³ The co-occurrence of leukemia and HIV/AIDS poses multifaceted challenges to patient care, necessitating a nuanced understanding of factors influencing disease trajectories. BMI serves as a tangible indicator of nutritional status, reflecting the balance between energy intake and expenditure. In leukemia patients with HIV/AIDS, maintaining optimal BMI assumes heightened significance due to the synergistic impact of these diseases on metabolic processes and immune function. Malnutrition, a prevalent complication in this population, not only compromises treatment tolerance and efficacy but also exacerbates susceptibility to opportunistic infections, thereby perpetuating a vicious cycle of disease progression.⁴⁻¹²

BMI variations exert profound effects on treatment responses and clinical outcomes in leukemia patients with HIV/AIDS. Low BMI is associated with heightened treatment-related toxicities, compromised hematopoietic recovery, and increased susceptibility to infectious complications. Conversely, elevated BMI may confer resistance to certain chemotherapeutic agents and escalate the risk of metabolic disorders such as insulin resistance and dyslipidemia. The intricate interplay between BMI dynamics and treatment responses underscores the need for personalized therapeutic approaches tailored to individual patient profiles.¹³⁻²⁶ Moreover, BMI serves as a surrogate marker of immune competence, with deviations from the norm reflecting underlying immunological dysfunction. In leukemia patients with HIV/AIDS, aberrant BMI trajectories are indicative of dysregulated cytokine profiles, impaired lymphocyte subsets, and compromised immune surveillance. Suboptimal BMI not only predisposes individuals to disease progression and treatment failure but also heightens the risk of opportunistic infections and malignancies. Consequently, optimizing BMI status emerges as a critical determinant of long-term clinical outcomes and survival in this vulnerable population.²⁷⁻³⁵ The complex interplay between BMI variations, treatment responses, and immunological function underscores the importance of adopting a multidisciplinary approach to patient care. Integrating nutritional support, pharmacological interventions, and psychosocial care is essential for addressing the diverse needs of leukemia patients with HIV/AIDS. Tailored nutritional supplementation strategies aimed at optimizing BMI status can mitigate treatment-related toxicities, enhance treatment tolerance, and bolster immune function. Furthermore, behavioral interventions targeting underlying determinants of malnutrition are indispensable for promoting holistic patient well-being and improving treatment outcomes.³⁶⁻⁴¹

Body Mass Index and Nutritional Status

Body Mass Index (BMI) serves as a fundamental metric in assessing the nutritional status of individuals, providing valuable insights into their overall health and well-being. Defined as the ratio of an individual's weight to the square of their height, BMI offers a simple yet effective means of categorizing individuals into different weight status categories, including underweight, normal weight, overweight, and obesity. In the context of leukemia patients with HIV/AIDS, BMI assumes particular significance due to the profound impact of these diseases on metabolic processes,

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

nutrient utilization, and immune function.⁴²⁻⁴⁸ Leukemia, a malignancy characterized by abnormal proliferation of blood cells, and HIV/AIDS, a viral infection that compromises immune function, often intersect to create a complex clinical scenario marked by heightened susceptibility to malnutrition and its associated complications. The synergistic effects of these diseases on metabolism, coupled with the debilitating side effects of chemotherapy and antiretroviral therapy, predispose patients to nutritional deficits and weight loss. As a result, maintaining optimal BMI levels becomes a crucial therapeutic goal, as it is closely linked to treatment tolerance, response rates, and overall survival outcomes.⁴⁹⁻⁵³ Malnutrition, a common occurrence in leukemia patients with HIV/AIDS, not only exacerbates the side effects of treatment but also compromises immune function, increasing the risk of opportunistic infections and treatment-related complications. Low BMI levels are often indicative of underlying nutritional deficiencies, including protein-energy malnutrition, micronutrient deficiencies, and cachexia, all of which can adversely affect treatment outcomes and quality of life. Conversely, elevated BMI may be associated with metabolic abnormalities such as insulin resistance, dyslipidemia, and cardiovascular disease, further complicating the management of these patients.⁵⁴⁻⁵⁹

Optimizing nutritional status in leukemia patients with HIV/AIDS requires a comprehensive approach that addresses both dietary intake and metabolic needs. Nutritional assessment, including evaluation of BMI, dietary intake, and biochemical markers, plays a crucial role in identifying patients at risk of malnutrition and guiding appropriate interventions. Tailored nutritional supplementation, including oral nutritional supplements, enteral feeding, and parenteral nutrition, may be necessary to meet the increased energy and protein requirements of these patients and mitigate the effects of malnutrition on treatment outcomes.⁶⁰⁻⁶² Furthermore, nutritional counseling and support are essential components of care for leukemia patients with HIV/AIDS, providing education on healthy eating habits, dietary modifications, and strategies to manage treatment-related side effects. Multidisciplinary collaboration among oncologists, infectious disease specialists, dietitians, and other healthcare providers is essential to ensure coordinated and individualized care that addresses the diverse needs of these patients. By addressing the nutritional needs of leukemia patients with HIV/AIDS and optimizing their BMI status, healthcare providers can improve treatment tolerance, enhance treatment outcomes, and ultimately, improve the quality of life for these individuals.⁶³⁻⁶⁷

Impact of BMI on Treatment Response

The impact of Body Mass Index (BMI) on treatment response in leukemia patients with HIV/AIDS is multifaceted, encompassing both physiological and pharmacokinetic considerations that influence therapeutic outcomes. BMI serves as a surrogate marker of metabolic health and nutritional status, influencing the pharmacodynamics and pharmacokinetics of chemotherapy agents and antiretroviral medications, thereby shaping treatment responses and clinical outcomes.⁶⁸⁻⁷¹ Low BMI levels are often associated with diminished treatment tolerance and increased susceptibility to treatment-related toxicities in leukemia patients with HIV/AIDS. Malnutrition, characterized by inadequate dietary intake and altered nutrient metabolism, compromises the body's ability to withstand the cytotoxic effects of chemotherapy and antiretroviral therapy. As a result, patients with low BMI may experience higher rates of treatment

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

interruptions, dose reductions, and treatment-related complications, leading to suboptimal treatment responses and poorer survival outcomes.⁷²⁻⁷⁶

Furthermore, BMI variations can impact the distribution, metabolism, and excretion of chemotherapy agents and antiretroviral medications, influencing drug exposure and efficacy. In patients with low BMI, altered drug metabolism and distribution may result in subtherapeutic drug levels, reducing the effectiveness of treatment and increasing the risk of disease progression and relapse. Conversely, in patients with elevated BMI, altered drug metabolism and distribution may lead to increased drug exposure and toxicity, necessitating dose adjustments and careful monitoring to minimize adverse effects. The relationship between BMI and treatment response is further complicated by the presence of comorbidities commonly observed in leukemia patients with HIV/AIDS, such as metabolic syndrome, insulin resistance, and dyslipidemia. These comorbidities can affect drug metabolism and distribution, exacerbating treatment-related toxicities and compromising treatment efficacy. Additionally, the immune dysregulation associated with HIV/AIDS can impact the body's ability to mount an effective antitumor response, further influencing treatment outcomes in this patient population.⁷⁷⁻⁸⁷ Optimizing treatment responses in leukemia patients with HIV/AIDS requires a personalized approach that takes into account BMI status, nutritional status, comorbidities, and immune function. Tailored treatment regimens, including dose adjustments based on BMI and pharmacokinetic parameters, may be necessary to achieve optimal therapeutic outcomes while minimizing treatment-related toxicities. Additionally, supportive care measures, including nutritional supplementation, management of comorbidities, and psychosocial support, play a crucial role in enhancing treatment tolerance and improving treatment responses in this vulnerable population.⁸⁸⁻⁹²

Immunological Implications

The immunological implications of Body Mass Index (BMI) variations in leukemia patients with HIV/AIDS are profound, reflecting the intricate interplay between metabolic health, nutritional status, and immune function. BMI serves as a surrogate marker of immune competence, with deviations from the norm indicative of underlying immunological dysfunction. In leukemia patients with HIV/AIDS, aberrant BMI trajectories are associated with dysregulated cytokine profiles, disrupted lymphocyte subsets, and impaired immune surveillance, all of which have significant implications for disease progression, treatment response, and overall prognosis.⁹³⁻⁹⁷ Low BMI levels are often indicative of malnutrition and immune compromise in leukemia patients with HIV/AIDS. Malnutrition impairs the production and function of immune cells, including T cells, B cells, and natural killer cells, compromising the body's ability to mount an effective immune response against leukemia cells and opportunistic infections. Consequently, patients with low BMI may experience more frequent and severe infections, higher rates of treatment-related complications, and poorer long-term outcomes compared to those with normal or elevated BMI.⁹⁸⁻¹⁰² Conversely, elevated BMI levels are associated with chronic inflammation and immune dysregulation, which can contribute to disease progression and treatment resistance in leukemia patients with HIV/AIDS. Adipose tissue serves as a reservoir for pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), which can promote leukemia cell proliferation, survival, and resistance to chemotherapy. Additionally, adipose tissue dysfunction

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

and insulin resistance, commonly observed in patients with elevated BMI, can further exacerbate immune dysfunction and impair treatment responses.¹⁰³⁻¹⁰⁷

The immunological implications of BMI variations extend beyond the direct effects on immune function to impact the efficacy of immunotherapy and other immune-based treatments in leukemia patients with HIV/AIDS. Immunotherapeutic approaches, such as checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and therapeutic vaccines, rely on intact immune function for their effectiveness. Therefore, BMI-related alterations in immune function and inflammatory status may influence the response to immunotherapy and contribute to variability in treatment outcomes among patients with different BMI levels.¹⁰⁸⁻¹¹² Addressing the immunological implications of BMI variations in leukemia patients with HIV/AIDS requires a comprehensive approach that integrates nutritional support, immunomodulatory therapies, and supportive care measures. Optimizing BMI status through nutritional supplementation and dietary interventions may help restore immune function and enhance treatment responses in malnourished patients. Additionally, targeted immunomodulatory therapies aimed at mitigating chronic inflammation and restoring immune homeostasis may hold promise for improving outcomes in patients with elevated BMI.¹¹³⁻¹¹⁹

Conclusion

Body Mass Index (BMI) variations play a pivotal role in shaping the clinical outcomes of leukemia patients with HIV/AIDS, reflecting the intricate interplay between metabolic health, immune function, and treatment responses. Optimal BMI status serves as a barometer of nutritional adequacy and immune competence, with deviations from the norm indicating underlying vulnerabilities that impact disease progression and treatment outcomes. Low BMI levels are often associated with malnutrition, immune compromise, and heightened treatment-related toxicities, leading to poorer treatment responses and survival outcomes in leukemia patients with HIV/AIDS. Conversely, elevated BMI levels may signify chronic inflammation, metabolic dysfunction, and treatment resistance, further complicating the management of these patients and diminishing treatment efficacy.

References

1. Zhao Y, Forst CV, Sayegh CE, Wang IM, Yang X, Zhang B. Molecular and genetic inflammation networks in major human diseases. *Molecular BioSystems*. 2016;12(8):2318-2341.
2. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. *Annu. Rev. Immunol.* 2004; 22:625-655.
3. Tulchinsky TH, Varavikova EA. Measuring, monitoring, and evaluating the health of a population. *The New Public Health*. 2014:91.
4. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. *Int. J. Curr. Res. Biol. Med.* 2023; 1:17-22.
5. Obeagu EI, Nakyeyune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

- hospital in Uganda. Madonna University journal of Medicine and Health Sciences. 2022;2(3):58-63.
6. Obeagu EI, Obeagu GU. Studies on platelets diagnostic indexes in patients with acute myeloid leukaemia in Uganda. Int. J. Curr. Res. Med. Sci. 2023;9(1):24-7.
 7. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. Journal home page: <http://www.journalijar.com>. 2022;10(03).
 8. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
 9. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
 10. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://www.researchgate.net/publication/36853864252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).
 11. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
 12. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
 13. Obeagu EI, Obeagu GU. The Impact of Body Mass Index (BMI) on Immune Function in Leukemia Patients Living with HIV: A Review. Elite Journal of Immunology. 2024;2(4):73-92.
 14. Obeagu EI, Obeagu GU. The Nexus Between Obesity and Leukemia Progression in HIV-Positive Individuals: A Review. Elite Journal of Haematology, 2024; 2 (4):180-98.
 15. Jolles S, Giralt S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, Reiser M, Ria R, Vinh DC, Wingard JR. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel. Blood Reviews. 2023; 58:101020.
 16. Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology: WJG. 2015;21(27):8293.
 17. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets and Some Inflammation Markers Of Patients With Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
 18. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. Int. J. Curr. Res. Med. Sci. 2021;7(7):29-41.
 19. Anyiam AF, Musa Muhibi MA, Iyare G, Omosigho PO, Olaniyan MF, Arinze-Anyiam OC, Oluwafemi E, Obeagu EI. Effects of different Extracts of Phyllanthus amarus on

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. Elite Journal of Health Science, 2024; 2(4): 59-72

- selected haematological and haemostatic parameters of Leukemic Wistar Rats. *Elite Journal of Medica Science*. 2024;2(1):23-43.
20. Obeagu EI, Udemezue EC, Akalonu BO, Babar Q. Plasma Cell Leukaemia (PCL): A Review. *Asian Hematology Research Journal*. 2021;5(3):36-8.
 21. Obeagu EI, Obeagu GU, Amilo GI. Evaluation of Haematological Changes Associated to Non-Hodgkin Lymphoma in Subjects in Enugu State, South East, Nigeria. *Arch Blood Transfus Disord*. 2017; 1:1-4.
 22. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.1007/s12245-022-1000-0).
 23. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
 24. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
 25. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
 26. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1007/s12245-016-0464-7).
 27. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, De Wit TD, Eichinger S, Fibbe W, Green T, De Haas F. The European hematology association roadmap for European hematology research: a consensus document. *haematologica*. 2016;101(2):115.
 28. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-167.
 29. Abunimye DA, Okafor IM, Okorowo H, Obeagu EI. The role of GATA family transcriptional factors in haematological malignancies: A review. *Medicine*. 2024;103(12): e37487.
 30. Obeagu EI, Okoroiwu IL, Daniel-Igwe G, Nnah IS. Hematology in the Senescence. *European Journal of Biomedical and Pharmaceutical Sciences*. 2015;2(3):97-107.
 31. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
 32. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

33. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.iosrjournals.org/IOSR-BP/papers/Vol12Issue04/1204070-75.pdf)
34. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
35. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311111111/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
36. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
37. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/328888888/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
38. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
39. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
40. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://www.researchgate.net/publication/368888888/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
41. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
42. Gutin I. In BMI we trust: reframing the body mass index as a measure of health. Social Theory & Health. 2018; 16:256-271.

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. Elite Journal of Health Science, 2024; 2(4): 59-72

43. Wynne C, Comiskey C, Hollywood E, Quirke MB, O'Sullivan K, McGilloway S. The relationship between body mass index and health-related quality of life in urban disadvantaged children. *Quality of Life Research*. 2014; 23:1895-1905.
44. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 2022;29-34.
45. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International*. 2020;32(24):9-18.
46. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.2196/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
50. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
53. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023;6(1):203-211.
<http://research.sdpublishers.net/id/eprint/2819/>.
54. Parisi E, Glick M. Immune suppression and considerations for dental care. *Dental Clinics*. 2003;47(4):709-731.
55. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
56. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
57. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
58. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.researchgate.net/publication/301111111_BIOCHEMICAL_ALTERATIONS_IN_ADULT_HIV_PATIENTS_ON_ANTIRETROVIRAL_THERAPY).
59. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
60. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8.DOI: [10.22192/ijcrps.2019.06.12.004](https://doi.org/10.22192/ijcrps.2019.06.12.004)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.researchgate.net/publication/350000000_Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence).
61. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462ed8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.researchgate.net/publication/36454462ed8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections).
62. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*.

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

- 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ejhs.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
63. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
 64. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
 65. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
 66. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
 67. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
 68. Joseph J, Sandel G, Kulkarni R, Alatrash R, Herrera BB, Jain P. Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS. *Pathogens.* 2023;13(1):14.
 69. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
 70. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
 71. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
 72. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
 73. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
 74. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

75. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
76. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
77. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
78. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
79. Echefu SN, Udosen JE, Akwivu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
80. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
81. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
82. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
83. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
84. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
85. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
86. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
87. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
88. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.
89. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):46-58.

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

90. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
91. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>*;12(01).
92. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
93. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. *The international journal of tuberculosis and lung disease*. 2004;8(3):286-298.
94. Knight ET, Liu J, Seymour GJ, Faggion Jr CM, Cullinan MP. Risk factors that may modify the innate and adaptive immune responses in periodontal diseases. *Periodontology* 2000. 2016;71(1):22-51.
95. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>*;12(01).
96. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV*. 2024;2(1):31-50.
97. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
98. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
99. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
100. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
101. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
102. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
103. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
104. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
105. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
106. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.

Citation: Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV/AIDS: A Review. *Elite Journal of Health Science*, 2024; 2(4): 59-72

107. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
108. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
109. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: <http://www.journalijar.com>;12(01).
110. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
111. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
112. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
113. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
114. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
115. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
116. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
117. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.
118. Obeagu EI. Aplastic Anemia and HIV: Clinical Features and Risk Factors. *Elite Journal of Haematology*, 2024; 2(5): 20-38
119. Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 39-54